Wells Fargo’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$553K Sell
67,885
-98,664
-59% -$894K ﹤0.01% 4103
2025
Q4
$1.12M Sell
166,549
-162,679
-49% -$1.23M ﹤0.01% 3880
2025
Q3
$2.85M Sell
329,228
-337,336
-51% -$2.63M ﹤0.01% 3059
2025
Q2
$4.2M Buy
666,564
+499,438
+299% +$3.31M ﹤0.01% 2611
2025
Q1
$1.07M Buy
167,126
+41,281
+33% +$341K ﹤0.01% 3611
2024
Q4
$1.01M Buy
125,845
+29,981
+31% +$289K ﹤0.01% 3700
2024
Q3
$1.21M Buy
95,864
+37,383
+64% +$483K ﹤0.01% 3417
2024
Q2
$740K Buy
58,481
+15,334
+36% +$154K ﹤0.01% 3678
2024
Q1
$206K Buy
43,147
+10,574
+32% +$49K ﹤0.01% 4454
2023
Q4
$156K Sell
32,573
-182,062
-85% -$1.11M ﹤0.01% 4624
2023
Q3
$1.55M Sell
214,635
-57,110
-21% -$456K ﹤0.01% 2992
2023
Q2
$2.02M Buy
271,745
+78,178
+40% +$615K ﹤0.01% 2913
2023
Q1
$1.34M Buy
193,567
+178,161
+1,156% +$1.64M ﹤0.01% 3169
2022
Q4
$158K Sell
15,406
-1,391
-8% -$24.5K ﹤0.01% 4299
2022
Q3
$306K Buy
16,797
+2,361
+16% +$102K ﹤0.01% 3992
2022
Q2
$742K Sell
14,436
-21,994
-60% -$1.14M ﹤0.01% 3485
2022
Q1
$2.68M Sell
36,430
-22,301
-38% -$1.99M ﹤0.01% 3013
2021
Q4
$8.4M Buy
58,731
+5,583
+11% +$959K ﹤0.01% 2015
2021
Q3
$11M Sell
53,148
-24,522
-32% -$5.4M ﹤0.01% 2128
2021
Q2
$16.5M Sell
77,670
-12,908
-14% -$2.36M ﹤0.01% 1827
2021
Q1
$16.4M Sell
90,578
-11,621
-11% -$2.32M ﹤0.01% 1819
2020
Q4
$11.4M Sell
102,199
-50,510
-33% -$5.37M ﹤0.01% 1993
2020
Q3
$16.5M Sell
152,709
-2,195
-1% -$267K ﹤0.01% 1539
2020
Q2
$12.9M Buy
154,904
+130,423
+533% +$4.99M ﹤0.01% 1657
2020
Q1
$333K Buy
24,481
+7,626
+45% +$64.5K ﹤0.01% 4346
2019
Q4
$67K Sell
16,855
-33,464
-67% -$145K ﹤0.01% 5429
2019
Q3
$252K Buy
50,319
+9,395
+23% +$51.4K ﹤0.01% 4823
2019
Q2
$240K Buy
40,924
+9,127
+29% +$71.8K ﹤0.01% 4867
2019
Q1
$350K Buy
31,797
+18,942
+147% +$598K ﹤0.01% 4540
2018
Q4
$473K Buy
12,855
+2,578
+25% +$99.9K ﹤0.01% 4375
2018
Q3
$387K Sell
10,277
-16,611
-62% -$468K ﹤0.01% 4614
2018
Q2
$720K Buy
26,888
+1,489
+6% +$50.3K ﹤0.01% 4213
2018
Q1
$1.07M Buy
25,399
+2,087
+9% +$83.8K ﹤0.01% 3859
2017
Q4
$578K Buy
23,312
+970
+4% +$23.7K ﹤0.01% 4290
2017
Q3
$509K Buy
22,342
+5,256
+31% +$118K ﹤0.01% 4321
2017
Q2
$393K Sell
17,086
-100
-0.6% -$1.96K ﹤0.01% 4372
2017
Q1
$440K Buy
17,186
+449
+3% +$12.3K ﹤0.01% 4330
2016
Q4
$422K Buy
16,737
+2,851
+21% +$83.2K ﹤0.01% 4311
2016
Q3
$577K Sell
13,886
-8,783
-39% -$1.13M ﹤0.01% 3866
2016
Q2
$3.3M Buy
22,669
+4,254
+23% +$488K ﹤0.01% 2615
2016
Q1
$1.9M Buy
18,415
+5,264
+40% +$565K ﹤0.01% 2964
2015
Q4
$2.21M Sell
13,151
-155,991
-92% -$24M ﹤0.01% 2915
2015
Q3
$23.9M Sell
169,142
-116,601
-41% -$26.1M 0.01% 1177
2015
Q2
$63.7M Sell
285,743
-34,829
-11% -$6.12M 0.02% 691
2015
Q1
$53M Sell
320,572
-34,054
-10% -$5.53M 0.02% 766
2014
Q4
$42.1M Sell
354,626
-10,420
-3% -$1.09M 0.02% 846
2014
Q3
$30.4M Buy
365,046
+128,557
+54% +$11.6M 0.01% 1004
2014
Q2
$21.9M Buy
236,489
+76,769
+48% +$6.75M 0.01% 1219
2014
Q1
$14.5M Buy
+159,720
New +$17.8M 0.01% 1503
2013
Q4
Sell
-250
Closed -$16K 5864
2013
Q3
$16K Buy
+250
New +$14.1K ﹤0.01% 5018

Other funds holding NVAX

Wells Fargo's NVAX Position: Q1 2026 in Review

Wells Fargo reduced its Novavax (NVAX) stake by 59% in Q1 2026, selling an estimated $894K and leaving 67,885 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #4103.

Wells Fargo first reported a position in NVAX in Q3 2013 and has held it in 50 quarters since. The position peaked at $63.7M in Q2 2015. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Wells Fargo held 67,885 shares of Novavax worth $553K as of Q1 2026.
  • Wells Fargo sold 98,664 Novavax shares in Q1 2026, an estimated $894K.
  • Novavax made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4103 holding.
  • Wells Fargo first reported a position in Novavax in Q3 2013 and has held it in 50 quarters since.
  • Wells Fargo's Novavax position peaked at $63.7M in Q2 2015.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.